EcoDrugPlus

Fibroblast Growth Factor 2

Ensembl ID : ENSJJAG00000008668
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSJJAG00000013570
Gene Symbol: FGFR1
3 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSJJAG00000012859
Gene Symbol: FGFR2
3 Cross references
217 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSJJAG00000001873
Gene Symbol: FGFR3
3 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSJJAG00000000503
Gene Symbol: FGFR4
3 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSJJAG00000009276
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSJJAG00000004796
Gene Symbol: FLT3
3 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSJJAG00000017737
Gene Symbol: FLT4
3 Cross references
195 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSJJAG00000021601
Gene Symbol: FOLH1B
3 Cross references
210 Possible Orthologues:

Folate Receptor Alpha

Ensembl ID : ENSJJAG00000019600
Gene Symbol: FOLR1
3 Cross references
217 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSJJAG00000015980
Gene Symbol: FSHR
3 Cross references
199 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSJJAG00000010874
Gene Symbol: FFAR1
3 Cross references
138 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).